ChIP assays showed that the ability of P53 to bind to the miR-133a-3p promoter was further enhanced by Ly294002 treatment in FOXO1-overexpressing NPC cells (Supplementary Fig. S3O). Here, FOXO1 is linked to nasopharyngeal carcinoma.